PubMed · 2014 · 13 citations · 0 references
MedicinePharmacokineticsPharmacologyCancer PharmacologyChemotherapyClinical PharmacologyAdverse Effects Of ChemotherapyChemotherapy Drug AdministrationChemotherapy In Hematologic MalignanciesChemotherapy Toxicity ManagementCytotoxic ChemotherapyToxicity ManagementAcute Leukemia ChemotherapyAcute Myeloid Leukemia BiologyAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TreatmentChemotherapy-related ToxicityDose-limiting Hematologic ToxicityFebrile Neutropenia TreatmentPharmacokinetics Of Cytotoxic Chemotherapy
UNLABELLED: We herein report the case of a male patient with acute myeloid leukemia with fatal outcome attributable to pharmacokinetics of pegfilgrastim. CASE REPORT: An unexplained blast proliferation in a patient with acute myeloid leukemia following cytotoxic induction chemotherapy was investigated in depth. Myeloblast hyperstimulation was likely related to pegfilgrastim, the long half-life of which extended the duration of side-effects, resulting in massive and rapidly fatal leukemia cell proliferation. CONCLUSION: Pegfilgrastim can cause unexpected deleterious effects in acute myeloid leukemia. We, thus, recommend administering drugs with a shorter half-life, such as filgrastim or lenograstim, to reduce infection incidence in patients receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia.